BNP PARIBAS FINANCIAL MARKETS - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 191 filers reported holding REVANCE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,632,204
-70.9%
142,302
-35.8%
0.00%
-71.4%
Q2 2023$5,613,986
-42.9%
221,809
-27.3%
0.01%
-50.0%
Q1 2023$9,829,880
+139.0%
305,181
+37.0%
0.01%
+133.3%
Q4 2022$4,112,870
-98.2%
222,799
+1232.5%
0.01%
Q2 2022$231,084,000
+62.9%
16,721
+129.8%
0.00%
Q1 2022$141,882,000
-45.5%
7,276
-54.4%
0.00%
Q4 2021$260,549,000
-45.5%
15,965
-7.0%
0.00%
-100.0%
Q3 2021$478,300,000
+85.0%
17,168
+96.8%
0.00%
Q2 2021$258,609,000
-51.2%
8,725
-54.0%
0.00%
-100.0%
Q1 2021$530,463,000
+53.8%
18,979
+56.0%
0.00%0.0%
Q4 2020$344,869,000
-7.8%
12,169
-18.2%
0.00%0.0%
Q3 2020$374,058,000
+551.0%
14,879
+532.3%
0.00%
Q2 2020$57,460,000
-75.3%
2,353
-85.0%
0.00%
Q1 2020$232,286,000
+172.0%
15,695
+198.3%
0.00%
Q4 2019$85,386,000
+3.4%
5,261
-17.2%
0.00%
Q3 2019$82,615,000
+49.2%
6,355
+48.9%
0.00%
Q2 2019$55,356,000
-55.9%
4,268
-46.4%
0.00%
Q1 2019$125,434,000
+387.7%
7,959
+669.0%
0.00%
Q3 2018$25,720,000
-9.5%
1,0350.0%0.00%
Q2 2018$28,411,000
-83.3%
1,035
-81.3%
0.00%
Q1 2018$170,293,000
-67.7%
5,529
-62.5%
0.00%
-100.0%
Q4 2017$527,277,000
+406.0%
14,749
+554.9%
0.00%
Q3 2017$104,200,000
+71.5%
2,252
-2.1%
0.00%
Q2 2017$60,746,000
+2199.2%
2,301
+1711.8%
0.00%
Q1 2017$2,642,000
-88.9%
127
-88.9%
0.00%
Q4 2016$23,722,000
-6.0%
1,146
-26.4%
0.00%
Q3 2016$25,239,000
+89.4%
1,557
+58.9%
0.00%
Q2 2016$13,328,000
-90.1%
980
-75.1%
0.00%
Q4 2015$134,386,000
+37.5%
3,934
+19.8%
0.00%
Q3 2015$97,702,000
+134.6%
3,283
+152.2%
0.00%
Q2 2015$41,638,000
+924.8%
1,302
+564.3%
0.00%
Q1 2015$4,063,000
-48.5%
196
-52.0%
0.00%
Q3 2014$7,887,0004080.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders